CD19 and Alzheimer disease: A recent study has demonstrated a decreased number of B cells in the blood of AD patients, or B cell depletion in the early stage via intraperitoneal injection of anti-CD19/B220 antibodies into APP/PS1 transgenic mice markedly accelerates cognitive dysfunction and Aβ burden[131].